Nuvalent Inc. is a biopharmaceutical company. It focused on creating precisely targeted therapies for clinically proven kinase targets in cancer. The company's program pipeline includes ROS1-positive and ALK-positive NSCLC. Nuvalent Inc. is based in CAMBRIDGE, Mass.
| Revenue (Most Recent Fiscal Year) | -- |
| Net Income (Most Recent Fiscal Year) | $-260.76M |
| PE Ratio (Current Year Earnings Estimate) | -- |
| PE Ratio (Trailing 12 Months) | -- |
| PEG Ratio (Long Term Growth Estimate) | -- |
| Price to Sales Ratio (Trailing 12 Months) | -- |
| Price to Book Ratio (Most Recent Quarterly Book Value per Share) | 5.31 |
| Price to Cash Ratio (Most Recent Annual Cash Flow per Share) | -- |
| Pre-Tax Margin (Trailing 12 Months) | -- |
| Net Margin (Trailing 12 Months) | -- |
| Return on Equity (Trailing 12 Months) | -31.35% |
| Return on Assets (Trailing 12 Months) | -29.27% |
| Current Ratio (Most Recent Fiscal Quarter) | 14.48 |
| Quick Ratio (Most Recent Fiscal Quarter) | 14.48 |
| Debt to Common Equity (Most Recent Fiscal Quarter) | 0.00 |
| Inventory Turnover (Trailing 12 Months) | -- |
| Book Value per Share (Most Recent Fiscal Quarter) | $14.08 |
| Earnings per Share (Most Recent Fiscal Quarter) | $-1.18 |
| Earnings per Share (Most Recent Fiscal Year) | $-3.93 |
| Diluted Earnings per Share (Trailing 12 Months) | $-4.39 |
| Exchange | NASDAQ |
| Sector | Healthcare |
| Industry | Biotechnology |
| Common Shares Outstanding | 71.81M |
| Free Float | 62.82M |
| Market Capitalization | $5.37B |
| Average Volume (Last 20 Days) | 0.52M |
| Beta (Past 60 Months) | 1.42 |
| Percentage Held By Insiders (Latest Annual Proxy Report) | 12.52% |
| Percentage Held By Institutions (Latest 13F Reports) | 97.26% |
| Annual Dividend (Based on Last Quarter) | $0.00 |
| Dividend Yield (Based on Last Quarter) | 0.00% |